Fundraising Fox
Alerje
Detroit, US · Founded 2016 · 7 employees on LinkedIn · 8 known investors
Find your way into Alerje
Sign up to see every warm intro you have to Alerje
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alerje team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alerje develops FAIT, a mobile app and clinical platform for food allergy oral immunotherapy (OIT), offering dose tracking, HIPAA-compliant clinic messaging, and predictive insights. It serves families managing childhood food allergies and the allergy clinics coordinating their care.
Founders & leadership
Alerje was founded in 2016 by Javier Evelyn.
Board
Investors · 8
How we know: Backstage Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Chloe Capital's portfolio page · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Jumpstart Nova's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: press coverage · the VCSheet dataset · Not right? Tell us
How we know: Seae Ventures's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2M disclosed across 2 rounds · 2020–2023
▶$1.9MraisedAug 2023 · 19 investors · Other TechnologyRule 506(b)
- Javier EvelynExecutive Officer, Director
- Patti GlazaDirector
- Offering amount
- $2.6M
- Amount sold
- $1.9M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$75KraisedMay 2020 · 2 investors · Other TechnologyRule 506(b)
- Javier EvelynExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $75K
- Minimum investment
- $25K
- Proceeds to insiders
- $40K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2023 | $1M |
| National Science Foundation | Phase I | 2021 | $255.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Alerje do?
- Alerje develops FAIT, a mobile app and clinical platform for food allergy oral immunotherapy (OIT), offering dose tracking, HIPAA-compliant clinic messaging, and predictive insights. It serves families managing childhood food allergies and the allergy clinics coordinating their care.
- Who founded Alerje?
- Alerje was founded by Javier Evelyn in 2016.
- Who are Alerje's investors?
- Alerje's investors include Backstage Capital, Chloe Capital, ID Ventures, Jumpstart Nova, Michigan Rise, Seae Ventures, Blue Victor Capital, Techstars.
- How much funding has Alerje raised?
- Alerje has disclosed $2M raised across 2 rounds.
- Where is Alerje headquartered?
- Alerje is headquartered in Detroit, US.